Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

TearLab

TearLab
Phone: 001-855-832-7522
Fax: 001-858-812-0540
Web Address: www.tearlab.com

TearLab Corporation develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award winning TearLab Osmolarity System.

The TearLab Osmolarity System is the Gold Standard for diagnosing and managing Dry Eye Disease with a quantitative, objective endpoint. CMS Reimbursement – $46.80 per patient (in the U.S. only). CPT Code 83861. FDA 510(k) cleared. CLIA Waived. CE Marked.

TearLab Corporation

Further Resources

Close Popup